MX2009008264A - Compuestos espiro heterociclicos. - Google Patents
Compuestos espiro heterociclicos.Info
- Publication number
- MX2009008264A MX2009008264A MX2009008264A MX2009008264A MX2009008264A MX 2009008264 A MX2009008264 A MX 2009008264A MX 2009008264 A MX2009008264 A MX 2009008264A MX 2009008264 A MX2009008264 A MX 2009008264A MX 2009008264 A MX2009008264 A MX 2009008264A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- heterocyclic spiro
- medicaments
- spiro
- heterocyclic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La solicitud de patente se relaciona con compuestos heterocíclicos novedosos de la fórmula general (I), en la cual R, R1, R2, Q, T, n y p tienen las definiciones dadas con mayor detalle en la descripción, con un proceso para preparar los compuestos y con el uso de esos compuestos como medicamentos, particularmente inhibidores de la aldosterona sintasa.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07105246 | 2007-03-29 | ||
PCT/EP2008/053671 WO2008119744A1 (en) | 2007-03-29 | 2008-03-27 | Heterocyclic spiro-compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2009008264A true MX2009008264A (es) | 2009-08-12 |
Family
ID=38461947
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2009008264A MX2009008264A (es) | 2007-03-29 | 2008-03-27 | Compuestos espiro heterociclicos. |
Country Status (18)
Country | Link |
---|---|
US (1) | US8324235B2 (es) |
EP (1) | EP2134720B1 (es) |
JP (1) | JP5331789B2 (es) |
KR (1) | KR20090126310A (es) |
CN (1) | CN101711252A (es) |
AR (1) | AR066691A1 (es) |
AT (1) | ATE484507T1 (es) |
AU (1) | AU2008234957A1 (es) |
BR (1) | BRPI0809645A2 (es) |
CA (1) | CA2681978A1 (es) |
DE (1) | DE602008003015D1 (es) |
ES (1) | ES2354008T3 (es) |
MX (1) | MX2009008264A (es) |
PL (1) | PL2134720T3 (es) |
PT (1) | PT2134720E (es) |
RU (1) | RU2009139811A (es) |
TW (1) | TW200904416A (es) |
WO (1) | WO2008119744A1 (es) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2009151069A1 (ja) | 2008-06-12 | 2011-11-17 | 第一三共株式会社 | 4,7−ジアザスピロ[2.5]オクタン環構造を有するイミダゾチアゾール誘導体 |
EP2594557B1 (en) | 2009-05-28 | 2016-08-10 | Novartis AG | Substituted aminopropionic derivatives as neprilysin inhibitors |
MX2011012627A (es) | 2009-05-28 | 2011-12-14 | Novartis Ag | Derivados aminobutiricos sustituidos como inhibidores de nepralisina. |
ES2702524T3 (es) * | 2009-07-15 | 2019-03-01 | Beijing Betta Pharmaceuticals Co Ltd | Compuestos como miméticos de hipoxia, y composiciones, y usos de estos |
JO2967B1 (en) | 2009-11-20 | 2016-03-15 | نوفارتس ايه جي | Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors |
US8673974B2 (en) | 2010-11-16 | 2014-03-18 | Novartis Ag | Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors |
US8877815B2 (en) | 2010-11-16 | 2014-11-04 | Novartis Ag | Substituted carbamoylcycloalkyl acetic acid derivatives as NEP |
TWI627167B (zh) | 2011-07-08 | 2018-06-21 | 諾華公司 | 用於高三酸甘油酯個體治療動脈粥狀硬化之方法 |
EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
UY35144A (es) | 2012-11-20 | 2014-06-30 | Novartis Ag | Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca |
CN105073762B (zh) | 2013-02-14 | 2017-03-08 | 诺华股份有限公司 | 作为nep(中性内肽酶)抑制剂的取代的联苯丁酰膦酸衍生物 |
EP3024845A1 (en) | 2013-07-25 | 2016-06-01 | Novartis AG | Cyclic polypeptides for the treatment of heart failure |
UY35671A (es) | 2013-07-25 | 2015-02-27 | Novartis Ag | Bioconjugados de polipéptidos de apelina sintética |
SG11201704758XA (en) | 2015-01-23 | 2017-08-30 | Novartis Ag | Synthetic apelin fatty acid conjugates with improved half-life |
KR20190016971A (ko) * | 2016-06-10 | 2019-02-19 | 니혼 메디피직스 가부시키가이샤 | 심질환의 비침습적 화상 진단제 |
JOP20190086A1 (ar) | 2016-10-21 | 2019-04-18 | Novartis Ag | مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب |
JP2020528893A (ja) * | 2017-07-25 | 2020-10-01 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | グルコース−6−リン酸デヒドロゲナーゼ(g6pd)調節剤及びg6pd欠乏症の治療方法 |
UY38072A (es) | 2018-02-07 | 2019-10-01 | Novartis Ag | Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos |
CN113166204A (zh) | 2018-11-27 | 2021-07-23 | 诺华股份有限公司 | 作为治疗代谢障碍的蛋白质原转换酶枯草杆菌蛋白酶/kexin 9型(PCSK9)抑制剂的环状肽 |
EP3887363A1 (en) | 2018-11-27 | 2021-10-06 | Novartis AG | Cyclic pentamer compounds as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorder |
UY38485A (es) | 2018-11-27 | 2020-06-30 | Novartis Ag | Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9), método de tratamiento, uso y su preparación |
TW202333563A (zh) | 2021-11-12 | 2023-09-01 | 瑞士商諾華公司 | 用於治療疾病或障礙之二胺基環戊基吡啶衍生物 |
AR127698A1 (es) | 2021-11-23 | 2024-02-21 | Novartis Ag | Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200716636A (en) * | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Heterocyclic spiro-compounds |
TW200716634A (en) * | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Heterocyclic spiro-compounds |
-
2008
- 2008-03-27 EP EP08735533A patent/EP2134720B1/en not_active Not-in-force
- 2008-03-27 AU AU2008234957A patent/AU2008234957A1/en not_active Abandoned
- 2008-03-27 JP JP2010500283A patent/JP5331789B2/ja not_active Expired - Fee Related
- 2008-03-27 AT AT08735533T patent/ATE484507T1/de active
- 2008-03-27 PL PL08735533T patent/PL2134720T3/pl unknown
- 2008-03-27 RU RU2009139811/04A patent/RU2009139811A/ru not_active Application Discontinuation
- 2008-03-27 US US12/450,521 patent/US8324235B2/en not_active Expired - Fee Related
- 2008-03-27 WO PCT/EP2008/053671 patent/WO2008119744A1/en active Application Filing
- 2008-03-27 CA CA002681978A patent/CA2681978A1/en not_active Abandoned
- 2008-03-27 TW TW097110903A patent/TW200904416A/zh unknown
- 2008-03-27 AR ARP080101259A patent/AR066691A1/es unknown
- 2008-03-27 MX MX2009008264A patent/MX2009008264A/es active IP Right Grant
- 2008-03-27 CN CN200880010854A patent/CN101711252A/zh active Pending
- 2008-03-27 DE DE602008003015T patent/DE602008003015D1/de active Active
- 2008-03-27 ES ES08735533T patent/ES2354008T3/es active Active
- 2008-03-27 KR KR1020097022483A patent/KR20090126310A/ko not_active Application Discontinuation
- 2008-03-27 BR BRPI0809645-7A patent/BRPI0809645A2/pt not_active IP Right Cessation
- 2008-03-27 PT PT08735533T patent/PT2134720E/pt unknown
Also Published As
Publication number | Publication date |
---|---|
DE602008003015D1 (de) | 2010-11-25 |
PT2134720E (pt) | 2010-12-07 |
ES2354008T3 (es) | 2011-03-09 |
AR066691A1 (es) | 2009-09-09 |
ATE484507T1 (de) | 2010-10-15 |
CA2681978A1 (en) | 2008-10-09 |
TW200904416A (en) | 2009-02-01 |
JP2010522725A (ja) | 2010-07-08 |
CN101711252A (zh) | 2010-05-19 |
AU2008234957A1 (en) | 2008-10-09 |
US8324235B2 (en) | 2012-12-04 |
BRPI0809645A2 (pt) | 2014-09-23 |
PL2134720T3 (pl) | 2011-04-29 |
KR20090126310A (ko) | 2009-12-08 |
US20100144774A1 (en) | 2010-06-10 |
WO2008119744A1 (en) | 2008-10-09 |
JP5331789B2 (ja) | 2013-10-30 |
EP2134720A1 (en) | 2009-12-23 |
EP2134720B1 (en) | 2010-10-13 |
RU2009139811A (ru) | 2011-05-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2009008264A (es) | Compuestos espiro heterociclicos. | |
TW200716636A (en) | Heterocyclic spiro-compounds | |
TW200716634A (en) | Heterocyclic spiro-compounds | |
TW200716105A (en) | Imidazole compounds | |
TW200616623A (en) | Organic compounds | |
TW200611898A (en) | Organic compounds | |
TW200608978A (en) | Organic compounds | |
TW200611897A (en) | Organic compounds | |
MX2010009416A (es) | Compuestos heterociclicos como inhibidores de cxcr2. | |
WO2007065942A3 (en) | Bis-heterocyclic imidazolyl compounds | |
MY153880A (en) | Proline derivatives as cathepsin inhibitors | |
TW200745067A (en) | Novel compounds | |
MX2010001754A (es) | Derivados de azepina como inhibidores de gamma secretasa. | |
NZ598972A (en) | Spiro-indoline-piperidine derivatives as selective GPR-40 activators for treating diabetes | |
UA103625C2 (en) | 5-hetrocyclylalkyl-3-hydroxy-2-phenylcyclopent-2-enons as herbicides | |
MX2011007998A (es) | Nuevos herbicidas. | |
MY161132A (en) | Novel herbicides | |
MX2012006805A (es) | Indolil-piperidinil bencilaminas como inhibidores de beta-triptasa. | |
MX2009006533A (es) | Derivados de indolil-maleimida como inhibidores de cinasa. | |
MX2011007932A (es) | Herbicidas nuevos. | |
MX341849B (es) | Nitrilos espirociclicos como inhibidores de proteasa. | |
JO2673B1 (en) | Diosmetin compounds, method of preparation and pharmaceutical compositions | |
MY152030A (en) | Novel herbicides | |
JO2682B1 (en) | Derivatives of alkynil-8.1-naphthayridone, preparations thereof and therapeutic use thereof | |
NZ597483A (en) | N1-substituted-5-fluoro-2-oxopyrimidinone-1(2h)-carboxamide derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |